MXCT Stock — MaxCyte Inc

MaxCyte Inc (MXCT)

Updated October 16, 2026.

MXCT is a Stock. Total return is -92.4% over the past 5.2 years, 179.1 points behind SPY at 86.7%.

MaxCyte is a life sciences company that develops and commercializes cell engineering instruments and related consumables used in cell therapy development, drug discovery, and biomanufacturing. The company's product portfolio includes electroporation instruments of varying scales—from bench-top systems to large-volume processing platforms—along with disposable processing assemblies and accessories that enable customers to modify and process cells for therapeutic applications. As a publicly traded operating company, MaxCyte does not have a regular distribution schedule, and information on its dividend payments is not currently available.

MXCT performance versus SPY

Price and return data through 2026-10-16.

Total return is -92.4% over the past 5.2 years, 179.1 points behind SPY at 86.7%. Over the past year its total return — price change plus distributions reinvested — is -26.5%. Its deepest 1-year drawdown was 61.8%.

MXCT key facts

Asset type

Stock

Asset class

Equity

Inception date

07/30/2021

Distribution frequency

None

Last close

$1.30 (as of 2026-10-16)

Market cap

$134,168,068

Average volume

1006501.0

Beta

1.491

Payout ratio

0.0%

EPS

$-0.34

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

MXCT risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 61.8%.

Who may consider MXCT — and who may not

It is a weaker fit for investors who need monthly cash flow (MXCT does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on MXCT

• All tickers starting with M

Tagged: Healthcare.

Frequently asked questions